Report on the Deliberation Results December 3, 2012 Evaluation
... 1. Origin or history of discovery and usage conditions in foreign countries etc. The proposed product is a solution for injection containing a 7:3 molar ratio of Insulin Degludec (Genetical Recombination) (hereinafter, “insulin degludec”), a long-acting insulin analogue, and Insulin Aspart (Genetica ...
... 1. Origin or history of discovery and usage conditions in foreign countries etc. The proposed product is a solution for injection containing a 7:3 molar ratio of Insulin Degludec (Genetical Recombination) (hereinafter, “insulin degludec”), a long-acting insulin analogue, and Insulin Aspart (Genetica ...
A PERSPECTIVE OF PERIODONTAL SYSTEMIC RELATIONSHIPS FOR THE ASIAN PACIFIC REGION
... The 7th International meeting of the Asian Pacific Society of Periodontology was held in Beijing, China from 21-22 September 2007, immediately preceding the 8th National Conference of the Chinese Society of Periodontology. Over 360 delegates attended this APSP meeting making it one of the largest me ...
... The 7th International meeting of the Asian Pacific Society of Periodontology was held in Beijing, China from 21-22 September 2007, immediately preceding the 8th National Conference of the Chinese Society of Periodontology. Over 360 delegates attended this APSP meeting making it one of the largest me ...
Part 4 – ToR 8 Benefits and safety of insulin pump therapy
... difference did not reach the 0.5% reduction generally accepted to be of clinical significance (Clar 2010; Cummins 2010). However, there is no consensus on the best minimum clinical difference and a smaller reduction may be considered important from a public health perspective if achieved by most peo ...
... difference did not reach the 0.5% reduction generally accepted to be of clinical significance (Clar 2010; Cummins 2010). However, there is no consensus on the best minimum clinical difference and a smaller reduction may be considered important from a public health perspective if achieved by most peo ...
consensus statement on the care of patients with sickle cell disease
... hemoglobin <50 g/L or decrease in reticulocyte count below 80 x 109/L), hold hydroxyurea until recovery, and consider resuming hydroxyurea therapy at a reduced dose. - Individual treatment centres must define their own thresholds for unacceptable hematologic values. • Once the patient is on a stab ...
... hemoglobin <50 g/L or decrease in reticulocyte count below 80 x 109/L), hold hydroxyurea until recovery, and consider resuming hydroxyurea therapy at a reduced dose. - Individual treatment centres must define their own thresholds for unacceptable hematologic values. • Once the patient is on a stab ...
Cytomegalovirus in Solid Organ Transplantation
... Viral culture is highly specific for the diagnosis of CMV infection. However, its use is limited by its modest sensitivity and slow turn-around time (27). Tissue culture may take weeks before the virus can be detected. Shell-vial centrifugation assay has a relatively more rapid turn-around time, but ...
... Viral culture is highly specific for the diagnosis of CMV infection. However, its use is limited by its modest sensitivity and slow turn-around time (27). Tissue culture may take weeks before the virus can be detected. Shell-vial centrifugation assay has a relatively more rapid turn-around time, but ...
PROGERIA: A REVIEW Review Article
... inhibitors (FTIs), has been proposed, but their use has been mostly limited to animal models. A Phase II clinical trial using the FTI lonafarnib began in May 2007. In studies on the cells another anti-cancer drug, rapamycin, caused removal of progerin from the nuclear membrane through autophagy. It ...
... inhibitors (FTIs), has been proposed, but their use has been mostly limited to animal models. A Phase II clinical trial using the FTI lonafarnib began in May 2007. In studies on the cells another anti-cancer drug, rapamycin, caused removal of progerin from the nuclear membrane through autophagy. It ...
How to Use the Lantus® SoloSTAR® Pre-filled Insulin Pen
... Lantus®, is low blood sugar (hypoglycemia), which may be serious. Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia may be serious and life threatening. It may cause harm to your heart or brain. Other possible side effects may incl ...
... Lantus®, is low blood sugar (hypoglycemia), which may be serious. Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia may be serious and life threatening. It may cause harm to your heart or brain. Other possible side effects may incl ...
Lantus SoloSTAR pen Quick Reference Guide
... Lantus®, is low blood sugar (hypoglycemia), which may be serious. Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia may be serious and life threatening. It may cause harm to your heart or brain. Other possible side effects may incl ...
... Lantus®, is low blood sugar (hypoglycemia), which may be serious. Some people may experience symptoms such as shaking, sweating, fast heartbeat, and blurred vision. Severe hypoglycemia may be serious and life threatening. It may cause harm to your heart or brain. Other possible side effects may incl ...
Rare Diseases and Orphan Products: Accelerating Research and Development PREPUBLICATION COPY
... between needs and effective responses. As documented in this report, opportunities now exist to accelerate progress toward understanding the basis for many more rare diseases and for developing innovative medical approaches. For example, the genomic era some 20 years ago promised when it was launche ...
... between needs and effective responses. As documented in this report, opportunities now exist to accelerate progress toward understanding the basis for many more rare diseases and for developing innovative medical approaches. For example, the genomic era some 20 years ago promised when it was launche ...
the Work in Progress abstracts
... progressive disease, or other demographic characteristics that may be associated with a lower likelihood of participation in clinical trials. Several currently recruiting registry efforts, while representing an improvement, also either rely on self-selection by PALS or have limited capacity to ensur ...
... progressive disease, or other demographic characteristics that may be associated with a lower likelihood of participation in clinical trials. Several currently recruiting registry efforts, while representing an improvement, also either rely on self-selection by PALS or have limited capacity to ensur ...
H1 results 2015 clinical trials appendix PDF 2198KB
... Clinical Trials Appendix Q2 2015 Results Update The following information about AstraZeneca clinical studies in Phases I-IV has been created with selected information from clinicaltrials.gov to facilitate understanding of key aspects of our clinical programmes and is correct to the best of our knowl ...
... Clinical Trials Appendix Q2 2015 Results Update The following information about AstraZeneca clinical studies in Phases I-IV has been created with selected information from clinicaltrials.gov to facilitate understanding of key aspects of our clinical programmes and is correct to the best of our knowl ...
JAMES NEUBRANDER, MD, is board certified in environmental
... Sterman found that the higher the incidences of the SMR wave form, the lower the incidence of seizure behavior. The SMR has also been shown to coincide with a more relaxed psychophysiological state. In people, neurofeedback is used to train individuals to enhance suboptimal brain wave patterns. Usin ...
... Sterman found that the higher the incidences of the SMR wave form, the lower the incidence of seizure behavior. The SMR has also been shown to coincide with a more relaxed psychophysiological state. In people, neurofeedback is used to train individuals to enhance suboptimal brain wave patterns. Usin ...
AVANDAMET® PRODUCT INFORMATION (rosiglitazone
... shown to be no worse than control for the change in ejection fraction from baseline to week 52 in 224 type 2 diabetes mellitus patients with New York Heart Association (NYHA) Class I or II heart failure on oral background antidiabetic (mostly sulfonylureas) and heart failure therapy (mainly diuretic ...
... shown to be no worse than control for the change in ejection fraction from baseline to week 52 in 224 type 2 diabetes mellitus patients with New York Heart Association (NYHA) Class I or II heart failure on oral background antidiabetic (mostly sulfonylureas) and heart failure therapy (mainly diuretic ...
Lyme Times ILADS Publishes New Treatment Guidelines
... Could Borrelia’s genetic expressions of these unrecognized genes be the source of unique symptoms? We know that when the Lyme bacteria Borrelia burgdorferi enters a human host it preferentially expresses certain genes and suppresses others. This allows the bacteria to adapt to new environments withi ...
... Could Borrelia’s genetic expressions of these unrecognized genes be the source of unique symptoms? We know that when the Lyme bacteria Borrelia burgdorferi enters a human host it preferentially expresses certain genes and suppresses others. This allows the bacteria to adapt to new environments withi ...
Tumor Necrosis Factor Alpha Converting Enzyme
... (D’Haens et al., 1997). Compared to CD, UC presents discontinuous lesions less often, but these skip-lesions are routinely associated with the appendiceal orifice (D’Haens et al., 1997). Severe conditions of UC may result in ulcers with observable transmural inflammation. Diagnosis of Clinical IBD. ...
... (D’Haens et al., 1997). Compared to CD, UC presents discontinuous lesions less often, but these skip-lesions are routinely associated with the appendiceal orifice (D’Haens et al., 1997). Severe conditions of UC may result in ulcers with observable transmural inflammation. Diagnosis of Clinical IBD. ...
AHRQ Healthcare Horizon Scanning System – Status Updates
... Scanning Protocol and Operations Manual,” which is available on the Effective Health Care Web site (Protocol and Operations Manual). Briefly, broad scanning is performed for each priority condition to detect “leads” to interventions and innovations. Sets of questions are applied to determine whether ...
... Scanning Protocol and Operations Manual,” which is available on the Effective Health Care Web site (Protocol and Operations Manual). Briefly, broad scanning is performed for each priority condition to detect “leads” to interventions and innovations. Sets of questions are applied to determine whether ...
summary on porphyria
... Porphyria is confirmed".9 Translation: there are many anxious. He or she may be desperate to do anything to with seeming "high anxiety" or other "mental" illnesses avoid any stress whatsoever. that are not being properly If stress also appears to trigger diagnosed—perhaps because, in part, severe hu ...
... Porphyria is confirmed".9 Translation: there are many anxious. He or she may be desperate to do anything to with seeming "high anxiety" or other "mental" illnesses avoid any stress whatsoever. that are not being properly If stress also appears to trigger diagnosed—perhaps because, in part, severe hu ...
health effects of the toxic gas leak from the union carbide
... multisystem morbidities – eyes and lungs being the main target organs. At this, the Nation was shocked, facing unprecedented health problems of a totally new disease, as nothing was known about its pathogenesis, prognosis and treatment. It was feared that the toxic gas inhalation might lead to progr ...
... multisystem morbidities – eyes and lungs being the main target organs. At this, the Nation was shocked, facing unprecedented health problems of a totally new disease, as nothing was known about its pathogenesis, prognosis and treatment. It was feared that the toxic gas inhalation might lead to progr ...
product monograph humulin humulin® n humulin
... to the sides of the vial, or if the contents of the vial are clear and remain clear after the bottle is shaken or rotated. NOTE: The contents of the vial or cartridge of HUMULIN-R should be clear. Do not use if cloudy. A few patients who experienced hypoglycemic reactions after being transferred to ...
... to the sides of the vial, or if the contents of the vial are clear and remain clear after the bottle is shaken or rotated. NOTE: The contents of the vial or cartridge of HUMULIN-R should be clear. Do not use if cloudy. A few patients who experienced hypoglycemic reactions after being transferred to ...
Product Monograph Template - Standard
... to the sides of the vial, or if the contents of the vial are clear and remain clear after the bottle is shaken or rotated. NOTE: The contents of the vial or cartridge of HUMULIN-R should be clear. Do not use if cloudy. A few patients who experienced hypoglycemic reactions after being transferred to ...
... to the sides of the vial, or if the contents of the vial are clear and remain clear after the bottle is shaken or rotated. NOTE: The contents of the vial or cartridge of HUMULIN-R should be clear. Do not use if cloudy. A few patients who experienced hypoglycemic reactions after being transferred to ...
Report - Institute for Clinical and Economic Review
... For patients unable to take statins, or for patients taking statins but not meeting their LDL-C goals, additional drugs are available, with ezetimibe (Zetia®) being the most relevant for this review. Ezetimibe inhibits the absorption of cholesterol in the intestines. Meta-analyses of randomized tria ...
... For patients unable to take statins, or for patients taking statins but not meeting their LDL-C goals, additional drugs are available, with ezetimibe (Zetia®) being the most relevant for this review. Ezetimibe inhibits the absorption of cholesterol in the intestines. Meta-analyses of randomized tria ...
available pharmaceutical products
... merger attempt with Allos was ended in November 2011. On Nov 17, 2011, AMAG announced that it had hired Jefferies to explore all opportunities to enhance shareholder value. Frank Thomas, interim CEO of AMAG indicated: “We will expeditiously complete this process, which will include a parallel review ...
... merger attempt with Allos was ended in November 2011. On Nov 17, 2011, AMAG announced that it had hired Jefferies to explore all opportunities to enhance shareholder value. Frank Thomas, interim CEO of AMAG indicated: “We will expeditiously complete this process, which will include a parallel review ...
Diagnosis and management of glycogen storage disease type I: a
... after dental or other surgeries, as well as menorrhagia in menstruating females is caused by impaired platelet function and/ or an acquired von Willebrand–like disease.45 Reduced platelet adhesiveness, abnormal platelet aggregation, and impaired release of adenosine diphosphate in response to collag ...
... after dental or other surgeries, as well as menorrhagia in menstruating females is caused by impaired platelet function and/ or an acquired von Willebrand–like disease.45 Reduced platelet adhesiveness, abnormal platelet aggregation, and impaired release of adenosine diphosphate in response to collag ...
Inositol – Clinical Applications for Exogenous Use
... Recent advances in nutritional and biochemical research have documented inositol as an important dietary and cellular constituent. The processes involved in inositol metabolism and its derivatives in the tissues of mammals have been characterized in vivo as well as at the enzymatic level. Biochemica ...
... Recent advances in nutritional and biochemical research have documented inositol as an important dietary and cellular constituent. The processes involved in inositol metabolism and its derivatives in the tissues of mammals have been characterized in vivo as well as at the enzymatic level. Biochemica ...
PRODUCT MONOGRAPH HUMALOG HUMALOG 200 units/mL
... Stress or concomitant illness, especially infectious and febrile conditions may change insulin requirements. In these instances, patients should contact their physician and carefully control their blood glucose. To avoid transmission of disease, a cartridge or prefilled syringe should not be used b ...
... Stress or concomitant illness, especially infectious and febrile conditions may change insulin requirements. In these instances, patients should contact their physician and carefully control their blood glucose. To avoid transmission of disease, a cartridge or prefilled syringe should not be used b ...